RecruitingNCT04608357

Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients

Integrated Patient Avatars for Guiding Systemic Therapy Treatments: "Intuition-Free" Decisions in Metastatic Breast Cancer Patients

Sponsor

Sunnybrook Health Sciences Centre

Enrollment

25 participants

Start Date

Jul 21, 2021

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Metastatic Breast Cancer Breast Neoplasms Cancer, Breast

Summary

The investigators propose to use clinically validated patient avatar technology ("PDXovo") that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Age 18+.
Metastatic breast cancer irrespective of subtype.
Measurable disease as per RECIST 1.1 criteria.
Metastatic disease involving the lymph nodes and/or visceral organs is required.
Willingness to undergo a biopsy prior to the start of planned systemic therapy.

Exclusion Criteria2

Lack of feasibility to obtain a core biopsy of a metastatic site other than the bone (e.g. a metastatic lesion cannot be safely sampled due to proximity to vasculature).
Inability to provide informed consent.

Interventions

DIAGNOSTIC_TESTNeedle Core Biopsies

Not an interventional study

Locations(1)

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04608357

Related Trials

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892139 locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

NCT0661828763 locations